Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
E: investors.relations@vivalis.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
676
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,203.20 | 45.30 | 0.56% |
| CAC 40 | 8,022.33 | 20.62 | -0.26% |
| DAX 40 | 22,852.66 | 39.02 | -0.17% |
| Dow JONES (US) | 42,583.32 | 597.97 | 1.42% |
| FTSE 100 | 8,638.01 | 8.78 | -0.10% |
| HKSE | 23,905.56 | 215.84 | 0.91% |
| NASDAQ | 18,188.59 | 404.54 | 2.27% |
| Nikkei 225 | 37,608.49 | 68.57 | -0.18% |
| NZX 50 Index | 12,183.72 | 55.51 | 0.46% |
| S&P 500 | 5,767.57 | 100.01 | 1.76% |
| S&P/ASX 200 | 7,980.60 | 43.70 | 0.55% |
| SSE Composite Index | 3,370.03 | 5.20 | 0.15% |